Accuray (NASDAQ:ARAY) Stock Rating Lowered by StockNews.com

Accuray (NASDAQ:ARAY) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a report issued on Saturday.

Accuray Price Performance

Shares of NASDAQ:ARAY opened at $1.82 on Friday. Accuray has a twelve month low of $1.40 and a twelve month high of $2.95. The stock’s 50 day moving average is $2.09 and its 200-day moving average is $1.99. The company has a quick ratio of 0.88, a current ratio of 1.62 and a debt-to-equity ratio of 3.51. The firm has a market capitalization of $187.15 million, a price-to-earnings ratio of -36.40 and a beta of 1.46.

Accuray (NASDAQ:ARAY) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.03. Accuray had a negative net margin of 0.96% and a negative return on equity of 9.75%. Sell-side analysts forecast that Accuray will post 0.01 EPS for the current fiscal year.

Institutional Trading of Accuray

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ARAY. Mackenzie Financial Corp lifted its holdings in shares of Accuray by 1,123.1% in the fourth quarter. Mackenzie Financial Corp now owns 272,846 shares of the medical equipment provider’s stock valued at $540,000 after purchasing an additional 250,539 shares in the last quarter. Squarepoint Ops LLC raised its position in Accuray by 36.0% in the 4th quarter. Squarepoint Ops LLC now owns 61,804 shares of the medical equipment provider’s stock valued at $122,000 after buying an additional 16,368 shares during the last quarter. Two Sigma Investments LP bought a new position in Accuray during the 4th quarter valued at $144,000. Two Sigma Advisers LP boosted its holdings in Accuray by 41.9% during the 4th quarter. Two Sigma Advisers LP now owns 70,513 shares of the medical equipment provider’s stock worth $140,000 after acquiring an additional 20,813 shares during the last quarter. Finally, State of Wyoming boosted its holdings in Accuray by 102.6% during the 4th quarter. State of Wyoming now owns 99,679 shares of the medical equipment provider’s stock worth $197,000 after acquiring an additional 50,485 shares during the last quarter. 64.08% of the stock is owned by institutional investors.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.